E2 ModeratePreliminaryPEM not requiredPeer-reviewedReviewed
Characteristics of the formation of chronic fatigue syndrome and approaches to its treatment in young patients with focal brain damage.
Boiko, A N, Batysheva, T T, Matvievskaya, O V et al. · Neuroscience and behavioral physiology · 2007 · DOI
Quick Summary
This study looked at why people with brain injuries (from multiple sclerosis, stroke, infection, or trauma) develop severe fatigue. Researchers tested 50 patients and gave half of them a medication called Fezam to see if it would help. The medication reduced fatigue symptoms, especially in MS patients, with few side effects.
Why It Matters
This study examines neurobiological mechanisms of fatigue in acquired brain injury, which may provide insights into central mechanisms also relevant to ME/CFS. Understanding how different brain pathologies produce fatigue—and which treatments target specific underlying mechanisms—could inform therapeutic approaches for ME/CFS patients.
Observed Findings
- Fezam significantly reduced chronic fatigue severity, particularly in MS patients
- In encephalopathy patients, chronic fatigue severity correlated with depression severity
- MS patients showed changes in value-sense sphere associated with fatigue
- Neuropsychological testing revealed psychological/personality components more prominent in encephalopathy fatigue than MS fatigue
- Mild side effects occurred in 12% of treated patients (mostly sleep disturbances)
Inferred Conclusions
- Different brain lesion types generate fatigue through distinct mechanisms: depression-linked in encephalopathies, value-sense disturbance-linked in MS
- Fezam may address central mechanisms of fatigue in acquired brain injury, with greater efficacy in MS
- Psychological interventions should accompany pharmacotherapy in encephalopathy-related fatigue
Remaining Questions
- Does Fezam efficacy extend to ME/CFS, or is it specific to post-lesion fatigue mechanisms?
- What are the active mechanisms of piracetam and cinnarizine in reducing fatigue—are they psychological, vascular, or metabolic?
What This Study Does Not Prove
This study does not prove that Fezam is effective for ME/CFS, which has different etiology from post-injury fatigue. The absence of a control group means improvements could reflect placebo response, natural recovery, or reporting bias rather than drug efficacy. Correlation between fatigue and depression does not establish causation.
Tags
Symptom:Fatigue
Method Flag:Weak Case DefinitionSmall SampleMixed Cohort
Metadata
- DOI
- 10.1007/s11055-007-0005-8
- PMID
- 17294097
- Review status
- Editor reviewed
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.